<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Microbiol.</journal-id>
<journal-title>Frontiers in Microbiology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Microbiol.</abbrev-journal-title>
<issn pub-type="epub">1664-302X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fmicb.2022.887949</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Microbiology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Protective Effect of Poria Cocos Polysaccharides on Fecal Peritonitis-Induced Sepsis in Mice Through Inhibition of Oxidative Stress, Inflammation, Apoptosis, and Reduction of Treg Cells</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Wu</surname> <given-names>Yu</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="author-notes" rid="fn002"><sup>&#x02020;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1569294/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Li</surname> <given-names>Dai</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="author-notes" rid="fn002"><sup>&#x02020;</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Wang</surname> <given-names>Han</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1738073/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Wan</surname> <given-names>Xiaojian</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x0002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1434924/overview"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Anesthesiology and Intensive Care Medicine, Changhai Hospital, Naval Medical University</institution>, <addr-line>Shanghai</addr-line>, <country>China</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Anesthesiology, Bethune International Peace Hospital</institution>, <addr-line>Shijiazhuang</addr-line>, <country>China</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Michal Letek, Universidad de Le&#x000F3;n, Spain</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Nada Pejnovic, University of Belgrade, Serbia; Hamid Yousf Dar, Emory University, United States</p></fn>
<corresp id="c001">&#x0002A;Correspondence: Xiaojian Wan <email>wan_xiaojian&#x00040;yeah.net</email></corresp>
<fn fn-type="other" id="fn001"><p>This article was submitted to Infectious Agents and Disease, a section of the journal Frontiers in Microbiology</p></fn>
<fn fn-type="equal" id="fn002"><p>&#x02020;These authors have contributed equally to this work</p></fn></author-notes>
<pub-date pub-type="epub">
<day>27</day>
<month>05</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>13</volume>
<elocation-id>887949</elocation-id>
<history>
<date date-type="received">
<day>02</day>
<month>03</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>14</day>
<month>04</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2022 Wu, Li, Wang and Wan.</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Wu, Li, Wang and Wan</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license> </permissions>
<abstract>
<p>This study was conducted to investigate the potential pharmacological effects of Poria cocos polysaccharides (PCPs) on fecal-induced peritonitis (FIP) mice. Consequently, the fecal peritonitis (FP)-induced septic mice with the higher levels of tumor necrosis factor-&#x003B1; (TNF-&#x003B1;), interleukin 6 (IL-6), IL-1&#x003B2;, malondialdehyde (MDA), myeloperoxidase (MPO), histopathological lesion and bacterial burden, and lower levels of superoxide dismutase (SOD) and glutathione (GSH). Interestingly, PCP pre-treatment reduced inflammatory cytokines and oxidative stress in plasma and spleen and improved the resistance to FIP. Inflammatory infiltration and cell death in thymus or splenic tissue were alleviated with PCP pretreatment. Furthermore, Treg cells were moderated in the spleen with PCP pre-administration. In addition, PCP pretreatment downregulated Annexin-V in the thymus of FP-induced septic mice, and apoptosis of splenic cells was dose-dependent. In conclusion, PCPs have pharmacological and biological effects on FP-induced septic mice, and its molecular mechanism is related to antioxidative, anti-inflammation, anti-apoptosis, and the reduction of Treg activity in splenic cells.</p></abstract>
<kwd-group>
<kwd>Poria cocos polysaccharides</kwd>
<kwd>fecal-induced peritonitis</kwd>
<kwd>sepsis</kwd>
<kwd>oxidative</kwd>
<kwd>inflammation</kwd>
<kwd>apoptosis</kwd>
<kwd>Treg cells</kwd>
</kwd-group>
<counts>
<fig-count count="8"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="57"/>
<page-count count="12"/>
<word-count count="6978"/>
</counts>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="s1">
<title>Introduction</title>
<p>Sepsis is one of the leading causes of mortality and critical illness worldwide (van der Poll et al., <xref ref-type="bibr" rid="B44">2021</xref>) and was considered a major cause of health loss (Cecconi et al., <xref ref-type="bibr" rid="B5">2018</xref>), with nearly 50 million cases globally per year (Rudd et al., <xref ref-type="bibr" rid="B38">2020</xref>). It is reported that 18% of intensive care unit (ICU) patients are suspected of infection (Vincent et al., <xref ref-type="bibr" rid="B45">2020</xref>). At present, sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection. Peritonitis is the inflammation of the peritoneum, usually due to a bacterial or fungal infection. Fecal peritonitis (FP) and subsequent sepsis are major problems when admitted to the ICU (Athanazio, <xref ref-type="bibr" rid="B1">2003</xref>). The mortality rate with peritonitis and peritonitis-related sepsis at 28 days was 19.1%, increasing to 31.6% at 6 months (Tridente et al., <xref ref-type="bibr" rid="B42">2014</xref>). Despite the decades of intensive research and more than 200 randomized controlled trials, the underlying mechanisms are still not comprehensively understood and, therefore, there is still no entirely functional treatment that could save lives in patients with sepsis (Ngamsri et al., <xref ref-type="bibr" rid="B31">2021</xref>). Measures remain largely supportive, such as timely antibiotics, source control, resuscitation, and supportive care for organ dysfunction (Evans et al., <xref ref-type="bibr" rid="B10">2021</xref>).</p>
<p>Poria cocos are mainly native to East Asia and Southeast Asia as a kind of medicinal edible fungus, known as &#x0201C;Fu Ling&#x0201D; in Chinese, which has been used in traditional Chinese medicine for more than 2000 years (Wang et al., <xref ref-type="bibr" rid="B51">2013</xref>) and is contained in approximately 15% of traditional Chinese medicine preparations in the Chinese pharmacopeia (Zhu et al., <xref ref-type="bibr" rid="B57">2018</xref>). The bioactive components in Poria cocos include polysaccharides, triterpenoids, fatty acids, sterols, and enzymes (Li et al., <xref ref-type="bibr" rid="B23">2022</xref>). Poria cocos are found in plant polysaccharides, Poria cocos polysaccharides (PCPs), which shows that it accounts for 84% by weight among all constituents in the dried sclerotium (Li et al., <xref ref-type="bibr" rid="B24">2019</xref>), and it is also the main bioactive component in Poria cocos that has extensive biological activities, such as ameliorating phlegm and edema, relieving nephrosis and chronic gastritis, improving uneasiness of minds (Kobira et al., <xref ref-type="bibr" rid="B18">2012</xref>; Wang et al., <xref ref-type="bibr" rid="B50">2012</xref>; Nie et al., <xref ref-type="bibr" rid="B32">2020</xref>), antitumor (Wang et al., <xref ref-type="bibr" rid="B46">2015</xref>; Li et al., <xref ref-type="bibr" rid="B22">2020</xref>), hepatoprotection (Kim et al., <xref ref-type="bibr" rid="B17">2019</xref>; Wu et al., <xref ref-type="bibr" rid="B54">2019</xref>), immunomodulation (Pu et al., <xref ref-type="bibr" rid="B34">2019</xref>), anti-inflammation (Lee et al., <xref ref-type="bibr" rid="B20">2017</xref>), antioxidation (Wang et al., <xref ref-type="bibr" rid="B48">2016</xref>), antibacterial (Wang et al., <xref ref-type="bibr" rid="B47">2019</xref>), and invigorating the splenic functions for immune regulation (Shen et al., <xref ref-type="bibr" rid="B39">2005</xref>). Studies showed that PCP could elicit strong immune activity and a protective effect against immunosuppression (Zhang et al., <xref ref-type="bibr" rid="B56">2017</xref>; Guo et al., <xref ref-type="bibr" rid="B12">2018</xref>), with few side effects and rich resources (Nie et al., <xref ref-type="bibr" rid="B32">2020</xref>).</p>
<p>There are few effective therapeutic measures for sepsis, and refer to the pharmacological properties of PCP, we predicted that PCP can enhance host defenses and may be effective for the prevention of sepsis.</p>
</sec>
<sec sec-type="materials and methods" id="s2">
<title>Materials and Methods</title>
<sec>
<title>Materials and Reagents</title>
<p>The PCP was purchased from Beijing Solable Biotechnology (Batch No. SP8930) with a purity of &#x0003E;90%, blending with normal saline to 4 mg/ml paste. Tumor necrosis factor-&#x003B1; (TNF-&#x003B1;) (Catalog: BMS607-3), interleukin 6 (IL-6) (Catalog: KMC0061), IL-10 (Catalog: BMS614), and IL-1&#x003B2; (Catalog: BMS613) ELISA kits were purchased from eBioscience. Glutathione (GSH; Batch No. A006-2-1), superoxide dismutase (SOD; Batch No. A001-3-2), malondialdehyde (MDA; Batch No. A003-1-2), myeloperoxidase (MPO; Batch No. A044-1-1), and other detection kits were purchased from Nanjing Jiancheng Bioengineering Institute. FoxP3 (EPR22102-37, Batch No. ab215206) antibody was purchased from Abcam company, and anti-CD4 FITC (clone: GK1.5, Batch No. 11-0041-82), anti-CD25 PE (clone: PC61.5, Batch No. 12-0251-82), anti-FoxP3 APC (clone: FJK-16s, Batch No. 17-5773-82), Annexin-V (Batch No. 331200), and propidium iodide (PI) (Batch No. BMS500PI) were purchased from eBioscience company.</p>
</sec>
<sec>
<title>Animals and Models</title>
<p>Male C57Bl/6 mice (6&#x02013;8 weeks, 20 &#x000B1; 2 g) were purchased from the Animal Experimental Center of Naval Medical University (Shanghai, China) and fed at the animal center of Changhai Hospital Affiliated with Naval Medical University. The ambient temperature was maintained at 25 &#x000B1; 2&#x000B0;C and relative humidity at 60 &#x000B1; 10%, with 12 h light/dark cycle. Filtered water and rodent fodder <italic>ad libitum</italic> were freely available to all mice. This study was approved by the Institutional Animal Care and Use Committee at Naval Medical University and abided by NIH animal trial standards.</p>
<p>All the mice were randomly divided into three groups. The PCP-dosed group was taken PCP orally (200 mg/kg, 400 mg/kg) daily for 14 days, according to previous literature (Wu et al., <xref ref-type="bibr" rid="B53">2018</xref>). The PCP-free group and Sham group were intragastrically given with the same volume of normal saline for 14 days. Then, the male C57Bl/6 mice were taken, sacrificed by cervical dislocation, and their cecal feces were fish out, weighed, and diluted. According to our previous experiment and referring to relevant literature (Rosen et al., <xref ref-type="bibr" rid="B37">2019</xref>), mice in the PCP-dosed group and PCP-free group were given the dose of 1 mg/g excrement for 24 h to induce sepsis (fecal-induced peritonitis [FIP]). The mice in the Sham group were given an equal volume of normal saline. Survival rate and Murine Sepsis Score (MSS) were assessed over seven subsequent days.</p>
</sec>
<sec>
<title>Bacterial Burden Determination</title>
<p>Mice with or without PCP pretreatment were euthanized at 24 h post-fecal injection. The blood samples were with dilutions of 10<sup>3</sup> or 10<sup>5</sup> in 100 &#x003BC;l saline and coated on a 5% sheep blood agar plate. Similarly, the peritoneum was rinsed with 2 ml of sterile phosphate-buffered saline (PBS) and then the peritoneal lavage fluid was collected and diluted sequentially to 10<sup>5</sup>-fold or 10<sup>7</sup>-fold. Plates were incubated at 37&#x000B0;C for 24 h, and colony counts were expressed as colony forming units per milliliter (CFU/ml).</p>
</sec>
<sec>
<title>Cytokine Analysis</title>
<p>At the end of the experiment, mice were sacrificed by cervical dislocation before blood collection. Blood was taken from the heart and the plasma was prepared by centrifugation at 3,500 rpm at 4&#x000B0;C for 15 min. Circulating cytokine levels (e.g., TNF-&#x003B1;, IL-6, and IL-1&#x003B2;) were measured using commercial ELISA kits (eBioscience) followed by the manufacturer&#x00027;s instructions.</p>
</sec>
<sec>
<title>Morphological Determination</title>
<p>The spleen was fixed with 4% paraformaldehyde for histopathological stains, paraffin-coated splenic sections were stained with hematoxylin and eosin (H&#x00026;E), and histopathological changes were screened and imaged under an optical microscope. The inflammatory infiltration and cell death of splenic cells were observed in different visual fields in sections. By the immunohistochemical method, the dewaxed splenic sections were sealed with 5% bovine plasma albumin (BSA) at 37&#x000B0;C for 1 h and then incubated with diluted primary FoxP3 (1:1,000). Subsequently, the slices were incubated with manufacture-based Strept Avidin Biotin Complex (SABC) solution and then stained with diaminobenzidine dye and counter-stained with hematoxylin. Finally, the slices are mounted and imaging examined using an optical microscope by experienced pathologists, separately.</p>
</sec>
<sec>
<title>Evaluation of Oxidative Stress</title>
<p>Splenic tissues were homogenized using a homogenizer. Splenic MPO, MDA, glutathione peroxidase (GSH-Px), and SOD activity content and the contents of MPO, MDA, GSH, and SOD for plasma were estimated using the biochemical assay kits (JianCheng Bio Institute, Nanjing, China), according to the manufacturer&#x00027;s instructions.</p>
</sec>
<sec>
<title>Flow Cytometry for the Determination of Treg Expression</title>
<p>The splenic tissue was harvested, and single-cell suspensions were prepared for each sample containing 1<sup>&#x0002A;</sup>10<sup>9</sup> cells treated with cell lysis buffer (BD Pharm Lyse&#x02122;, AB_2869057, USA). Then, sections were stained with or without anti-CD4 and anti-CD25 and treated with FIX &#x00026; PERM medium A and B (Invitrogen, USA). Later, it was also stained with anti-FoxP3. A parallel control group was treated with isotype controls. Flow cytometry was performed using MACSQuant Analyzer (Miltenyi Biotec, Bergisch Gladbach, Germany), and data were analyzed using the Flowjo software version 10.0 (Tree Star, Ashland, OR, USA).</p>
</sec>
<sec>
<title>Determination of Apoptosis in the Thymus and Spleen</title>
<p>Samples of the thymus were harvested, and single-cell suspensions of the thymus were prepared. Annexin-V-positive cells were gated and considered apoptotic events. Cells were incubated with anti-CD3, Annexin V, and PI. A parallel control group was treated with isotype controls according to the manufacturer&#x00027;s recommendations.</p>
<p>The terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labeling (TUNEL) assay was used to assess the degree of splenocyte apoptosis. Formalin-fixed and paraffin-embedded splenic sections were stained using the TUNEL assay. This assay was performed by following the manufacturer&#x00027;s instructions for a commercially available kit (DAB TUNEL Cell Apoptosis Detection Kit, Batch No. G1507-50T, Servicebio, Wuhan, China) and evaluated by immunofluorescence staining. The reaction was stopped after incubation for 1 h at 37&#x000B0;C. The slices were washed followed by the addition of an anti-digoxigenin-peroxidase solution. The sections were then colorized with DAB/H<sub>2</sub>O<sub>2</sub> and counter-stained with bisbenzamide. Five random fields of view were assessed per section. The apoptotic index for each mouse was calculated as the percentage of TUNEL-positive cells (TUNEL-positive cell number/total splenic cell number &#x000D7; 100%).</p>
</sec>
<sec>
<title>Statistical Analysis</title>
<p>All data were analyzed using the GraphPad Prism version 8.0 software, and normal distribution was used in the Kolmogorov&#x02013;Smirnov test. Analysis of variance (ANOVA) was used to compare the differences between groups. The Bonferroni test was used as a <italic>post-hoc</italic> test for the correction of multiple comparisons. The final data were expressed as mean &#x000B1; standard deviation (SD). The log-rank test was performed to determine the significance of difference between the groups in the survival study. Differences between groups were considered statistically significant when <italic>P</italic> &#x0003C; 0.05.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<sec>
<title>Biological Benefits of PCP on FIP-Septic Mice</title>
<p>After successfully causing FP, all of the mice moved freely and none needed analgesia for pain immediately. We observed the survival rate and evaluated the clinical scores of mice by incorporating the MSS at 0, 1, 6, 12, 24, 48, 72, 96, 120, 144, and 168 h. The scoring criteria are as follows (Shrum et al., <xref ref-type="bibr" rid="B40">2014</xref>): spontaneous activity, response to touch and auditory stimuli, posture, respiration rate and quality (labored breathing or gasping), and appearance (i.e., degree of piloerection), each of these scores variables between 0 and 4, and the symptoms the severer, the score the higher. As shown in Mouse Scoring Systems after FP for 24 h later, FP-induced septic mice resulted in reducing Mouse Scoring Systems when compared to those in FIP-free mice (<italic>P</italic> &#x0003C; 0.05). As can be seen from <xref ref-type="fig" rid="F1">Figure 1</xref>, the MSS was correlated with the survival rate. A high MSS indicates that mice have severe infection symptoms and are prone to death.</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption><p>Poria cocos polysaccharide (PCP) pretreatment improved the 7-day survival and Murine Sepsis Score (MSS) of septic mice. <bold>(A)</bold> The survival of mice in the normal group was in good condition and the survival rate of mice decreased linearly after fecal injection. While the mice received PCP, the survival rate increased significantly, but the survival rate had no significant difference between receiving PCP of 200 and 400 mg/kg/day. <bold>(B)</bold> The MSS of experiment mice in each group. The MSS of mice increased significantly at 6 h after fecal injection, the upraise lasts for 24 h, and a peaked at 36 h after treatment. The MSS of PCP-treated mice increased less. Meanwhile, there was no difference in the MSS between PCP 200 and PCP 400 mg-treated mice. <sup>&#x0002A;</sup><italic>P</italic> &#x0003C; 0.05; <sup>&#x0002A;&#x0002A;</sup><italic>P</italic> &#x0003C; 0.01, FIP &#x0002B; PCP-200 = FIP with PCP 200 mg/kg/day; FIP &#x0002B; PCP-400 = FIP with PCP 400 mg/kg/day. <italic>n</italic> = 12.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmicb-13-887949-g0001.tif"/>
</fig></sec>
<sec>
<title>PCP Reduced Bacterial Burden</title>
<p>The capacity of bacterial clearance was assessed by measuring bacterial burden. The FP-induced septic mice with PCP 400 mg/kg/day pretreatment, bacterial burden levels in peripheral blood, and enterocoelia were reduced at 24 h post-fecal injection (<xref ref-type="fig" rid="F2">Figure 2</xref>).</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption><p>PCP-400 mg/kg/day pretreatment reduced the bacterial burden in peripheral blood <bold>(A)</bold> and at the enterocoelia <bold>(B)</bold>. No significant difference between PCP-400 mg/kg/day and PCP-200 mg/kg/day. All presented data are a composite of three independent experiments. &#x0002A;<italic>P</italic> &#x0003C; 0.05, <italic>n</italic> = 5 in each group.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmicb-13-887949-g0002.tif"/>
</fig></sec>
<sec>
<title>PCP Reduced Inflammatory Cytokines in FP-Induced Septic Mice</title>
<p>Notably, the FP-induced septic mice had significantly higher levels of TNF-&#x003B1;, IL-6, and IL-1&#x003B2; in plasma compared to the Sham-treated mice (<italic>P</italic> &#x0003C; 0.05). Following PCP pretreatment, these cytokine expressions were suppressed in a dose-dependent manner. The concentration was significantly reduced compared with the FIP septicemia control group (<italic>P</italic> &#x0003C; 0.05) (<xref ref-type="fig" rid="F3">Figure 3</xref>).</p>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption><p>PCP pretreatment inhibited the inflammatory response in FP-induced septic mice. <bold>(A)</bold> TNF-&#x003B1; in plasma in each group. <bold>(B)</bold> IL-6 in plasma in each group. <bold>(C)</bold> IL-1&#x003B2; in plasma in each group. &#x0002A;<italic>P</italic> &#x0003C; 0.05; &#x0002A;&#x0002A;<italic>P</italic> &#x0003C; 0.01, &#x0002A;&#x0002A;&#x0002A;<italic>P</italic> &#x0003C; 0.001, FIP &#x0002B; PCP-200 = FIP with PCP 200 mg/kg/day; FIP &#x0002B; PCP-400 = FIP with PCP 400 mg/kg/day. All presented data are a composite of three independent experiments. <italic>n</italic> = 5 in each group.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmicb-13-887949-g0003.tif"/>
</fig></sec>
<sec>
<title>PCP Influenced Oxidative Stress in Fecal Peritonitis-Induced Septic Mice</title>
<p>The oxidative stress in plasma and spleen was evaluated by GSH, MDA, MPO, and SOD levels through Elisa kits. The expressions of MPO and MDA levels were higher, while SOD and GSH levels were lower when intervened with feces injection. In contrast, PCP pretreatment reversed these manifestations, as shown in <xref ref-type="fig" rid="F4">Figure 4</xref>.</p>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption><p>PCP pretreatment inhibited the oxidative stress in fecal peritonitis-induced septic mice. <bold>(A)</bold> GSH in plasma in each group. <bold>(B)</bold> MDA in plasma in each group. <bold>(C)</bold> MPO in plasma in each group. <bold>(D)</bold> SOD in plasma in each group. <bold>(E)</bold> GSH in the spleen in each group. <bold>(F)</bold> MDA in the spleen in each group. <bold>(G)</bold> MPO in the spleen in each group. <bold>(H)</bold> SOD in the spleen in each group. &#x0002A;<italic>P</italic> &#x0003C; 0.05; &#x0002A;&#x0002A;<italic>P</italic> &#x0003C; 0.01, &#x0002A;&#x0002A;&#x0002A;<italic>P</italic> &#x0003C; 0.001, FIP &#x0002B; PCP-200 = FIP with PCP 200 mg/kg/day; FIP &#x0002B; PCP-400 = FIP with PCP 400 mg/kg/day. All presented data are a composite of three independent experiments. <italic>n</italic> = 5 in each group.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmicb-13-887949-g0004.tif"/>
</fig></sec>
<sec>
<title>PCP Suppresses Histopathological Changes in Fecal Peritonitis-Induced Septic Mice</title>
<p>The splenic injury was determined at 24 h post-fecal injection or Sham treatment. As shown in <xref ref-type="fig" rid="F5">Figure 5</xref>, FP induced substantial pathological lesions in the spleen. Pathological changes in the spleen showed vascular leakage, deranged tissue, cytoskeletal damage, necrosis, and inflammatory infiltration and cellular apoptosis following feces infection. PCP pretreatment largely alleviated the pathological lesions as compared to that in the Sham group (<xref ref-type="fig" rid="F5">Figure 5</xref>).</p>
<fig id="F5" position="float">
<label>Figure 5</label>
<caption><p>Histopathological lesions were determined in the spleen following fecal peritonitis-induced septic. Representative images showed an improvement in the vital organ injury in mice pretreated with PCP-400. Sections were examined under the microscope at a magnification of 200 &#x000D7; by two separate pathologists. The blue arrows indicate histopathological lesions and the black arrows refer to normal pathological appearance. <bold>(A)</bold> Sham. <bold>(B)</bold> FIP. <bold>(C)</bold> FIP &#x0002B; PCP-200. <bold>(D)</bold> FIP &#x0002B; PCP-400. FIP &#x0002B; PCP-200 = FIP with PCP 200 mg/kg/day; FIP &#x0002B; PCP-400 = FIP with PCP 400 mg/kg/day. All presented data are a composite of three independent experiments. <italic>n</italic> = 5 in each group.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmicb-13-887949-g0005.tif"/>
</fig></sec>
<sec>
<title>PCP Reduced Treg Cells in Fecal Peritonitis-Induced Septic Mice</title>
<p>To evaluate the changes in immune function in FIP sepsis mice, we observed the subtypes of splenic cells that fed and non-fed PCP by flow cytometry and immunohistochemical analysis. The results showed that FP increased the Treg cells, and pretreatment with PCP could largely alleviate the expression level of Treg cells as compared to that in the Sham group (<xref ref-type="fig" rid="F6">Figure 6</xref>).</p>
<fig id="F6" position="float">
<label>Figure 6</label>
<caption><p>The impact of PCP on Treg cells in the fecal peritonitis-induced septic spleen. PCP pretreatment contributed to decreased FoxP3 labeled cells and CD25<sup>&#x0002B;</sup>FoxP3<sup>&#x0002B;</sup> cells. <bold>(A&#x02013;D)</bold> Immunohistochemical analysis. <bold>(E&#x02013;H)</bold> Flow cytometry analysis. <bold>(A,E)</bold> Sham. <bold>(B,F)</bold> FIP. <bold>(C,G)</bold> FIP &#x0002B; PCP-200. <bold>(D,H)</bold> FIP &#x0002B; PCP-400. <bold>(I)</bold> Treg cells in the spleen. <bold>(J)</bold> FoxP3 positive cells in the spleen CD4&#x0002B; cells. &#x0002A;<italic>P</italic> &#x0003C; 0.05; &#x0002A;&#x0002A;<italic>P</italic> &#x0003C; 0.01, &#x0002A;&#x0002A;&#x0002A;<italic>P</italic> &#x0003C; 0.001, FIP &#x0002B; PCP-200 = FIP with PCP 200 mg/kg PCP; FIP &#x0002B; PCP-400 = FIP with PCP 400 mg/kg. All presented data are a composite of three independent experiments. <italic>n</italic> = 5 in each group.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmicb-13-887949-g0006.tif"/>
</fig></sec>
<sec>
<title>PCP Regulated Annexin-V and PI in FIP-Septic Mice&#x00027; Thymus</title>
<p>Apoptosis was determined in the thymus at 24 h post-FIP or Sham treatment. Flow cytometry and data analysis were performed to further determine the anti-apoptotic activity of PCP against FP-induced sepsis. The number of Annexin-V-positive T cells was extremely low in the thymus from the Sham group, and sepsis resulted in a marked increase in the number of apoptotic events. Importantly, with pretreatment with PCP, the number of Annexin-V-positive cells in the thymus was decreased in a dose-dependent manner (<italic>P</italic> &#x0003C; 0.05) (<xref ref-type="fig" rid="F7">Figure 7</xref>).</p>
<fig id="F7" position="float">
<label>Figure 7</label>
<caption><p>The impact of PCP on apoptosis in the fecal peritonitis-induced septic thymus. PCP pretreatment contributed to decreased Annexin-V, PI. <bold>(A)</bold> Sham group; <bold>(B)</bold> FIP; <bold>(C)</bold> FIP &#x0002B; PCP-200; <bold>(D)</bold> FIP &#x0002B; PCP-400. <bold>(E)</bold> Histogram of four groups. As shown, the differences between FIP and FIP &#x0002B; PCP-400 had a significant difference. &#x0002A;<italic>P</italic> &#x0003C; 0.05; &#x0002A;&#x0002A;&#x0002A;<italic>P</italic> &#x0003C; 0.001, FIP &#x0002B; PCP-200 = FIP with PCP 200 mg/kg/day; FIP &#x0002B; PCP-400 = FIP with PCP 400 mg/kg/day. All presented data are a composite of three independent experiments. <italic>n</italic> = 5 in each group.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmicb-13-887949-g0007.tif"/>
</fig></sec>
<sec>
<title>PCP Relieved Splenocyte Apoptosis in FIP-Septic Mice</title>
<p>To detect the level of splenocyte cell apoptosis in the FIP mouse in this study, a TUNEL assay of splenic tissue was performed. The fluorescence assay showed that TUNEL-positive cells were sporadically found in the Sham-treated mice, and the numbers significantly increased after the induction of septic peritonitis. TUNEL-positive cells were fertile in the FIP group, while significantly reduced in the PCP-pretreatment group. The apoptotic rate of splenocyte cells was reduced from 7.23 to 3.76% with PCP-400 mg/kg/day pretreatment (<xref ref-type="fig" rid="F8">Figure 8</xref>).</p>
<fig id="F8" position="float">
<label>Figure 8</label>
<caption><p>The impact of PCP on vital signs in the fecal peritonitis-induced septic spleen. PCP pretreatment contributed to decreased percentage of TUNEL-positive cells, <sup>&#x0002A;</sup><italic>P</italic> &#x0003C; 0.05; <sup>&#x0002A;&#x0002A;&#x0002A;</sup><italic>P</italic> &#x0003C; 0.001, FIP &#x0002B; PCP-200 = FIP with PCP 200 mg/kg; FIP &#x0002B; PCP-400 = FIP with PCP 400 mg/kg. All presented data are a composite of three independent experiments. <italic>n</italic> = 5 in each group.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmicb-13-887949-g0008.tif"/>
</fig></sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>Notably, many Chinese and East-Southeast Asia residents take traditional medicinal materials, such as &#x0201C;Poria Cocos polysaccharide,&#x0201D; daily to strengthen the body&#x00027;s resistance (Wu et al., <xref ref-type="bibr" rid="B53">2018</xref>). We verified the protective effect of PCP on FP-induced sepsis, which has important practical significance for East-Southeast Asia residents. This study found that the mice fed with PCP could better resist the feces and improve mice&#x00027;s clinical score and survival rate. A further study of this effect showed that the inflammation in mice was lower and there were fewer cytokines promoting inflammation when exposed to fecal. Meanwhile, pretreatment with PCPs, the level of oxidative stress was controlled well, and reactive oxygen species (ROS) were reduced. Then, the splenic injury was gentle, the apoptosis of splenocytes was less, the expression of Treg was reduced, and the splenic function to resist damage-associated molecular patterns (DAMPs) injury was maintained. This study provides a new concept for relieving FP-induced sepsis, given the feeble pretreatment regimen for sepsis based on the anti-inflammatory and protective effects of PCP. As a previous report, this study also compared different dose concentrations of PCP to verify the efficacy of different concentrations and suggested that the efficacy of 400 mg/kg/day PCP was better than that of 200 mg/kg/day.</p>
<p>Predominantly, sepsis is considered to be an acute inflammatory state mediated by the activation of the innate immune system caused by infection (Grondman et al., <xref ref-type="bibr" rid="B11">2020</xref>). Molecules derived from pathogens, also known as pathogen-associated molecular patterns (PAMPs), can bind to pattern recognition receptors (PRRs) to activate innate immune cells to protect the host. The activation of PRRs on innate or non-immune cells can trigger intracellular signal cascades, thus activating transcription factors (Wang and Wang, <xref ref-type="bibr" rid="B49">2013</xref>). Intracellular signaling cascades initiate multiple cellular processes, including cytokine production. There are many different PRRs subsets on immune cells (mainly monocytes/macrophages) and non-immune cells that recognize different classes of microorganisms, leading to immune activation (Mahla et al., <xref ref-type="bibr" rid="B28">2013</xref>). Early stage sepsis, the initial hyperinflammatory phase, also known as the &#x0201C;cytokine storm,&#x0201D; is &#x02018;described by the overwhelming release of inflammatory molecules by the innate immune system (Chaturvedi et al., <xref ref-type="bibr" rid="B6">2021</xref>). Hyperinflammation is to induce the initial cause of cell impairment, causing necrotic cells and tissue injury from the original insult and inflammatory reaction (Gustine and Jones, <xref ref-type="bibr" rid="B13">2021</xref>). The TNF-&#x003B1; is an endogenous pyrogen involved in the induction of fever, apoptotic cell death, and inflammation. IL-6 is an important mediator that acts as a pro-inflammatory cytokine (Lonsdale et al., <xref ref-type="bibr" rid="B27">2020</xref>). Meanwhile, the body promotes the secretion level of inflammatory factors (TNF-&#x003B1;, IL-6, and IL-1&#x003B2;) and decreases the secretion level of inflammatory factors, making the body&#x00027;s immune system in a state of immune hyperactivity and cope with the pathogens (London et al., <xref ref-type="bibr" rid="B26">2010</xref>). While this state of affairs continued, the body has been high pro-inflammation factors, and the body&#x00027;s immune cells appear to reduce the number of cells and loss of function to make the body&#x00027;s immune chaos and paralysis, accelerating the death of patients (van der Poll et al., <xref ref-type="bibr" rid="B44">2021</xref>). Therefore, controlling the excessive inflammation in the early stage is significant in sepsis (Bosmann and Ward, <xref ref-type="bibr" rid="B4">2013</xref>). After 14 days of feeding with PCP, mice were intraperitoneally injected with excrement and sacrificed 24 h later. Compared with the mice without feeding PCP, the secretion levels of promoting inflammatory factors were reduced. It indicates that daily administration of PCP can resist the FP and has a good protective effect.</p>
<p>Oxidative stress is a result of an imbalance between the formation of reactive oxidizing species, such as superoxide, hydrogen peroxide, and hydroxyl ions as free radicals, and the removal of antioxidant scavengers, such as catalase, SOD, vitamin C, vitamin E, and reduced GSH (Pizzino et al., <xref ref-type="bibr" rid="B33">2017</xref>; Usmani et al., <xref ref-type="bibr" rid="B43">2021</xref>). In septic conditions, the body needs more energy to sustain life activities than it normally does. Mitochondria generate a large number of oxygen free radicals while providing energy through the electron transport chain (Ramirez-Zuniga et al., <xref ref-type="bibr" rid="B36">2021</xref>). In a physiological state, mitochondria can avoid the damage of ROS by the antioxidant enzymes, such as SOD and GSH. As one of the most important oxygen free radicals in the ROS family, MDA is the main degradation product of lipid peroxidation. By attacking the unsaturated fatty acids in the cell membrane, MDA inhibits the function of membrane protein and leads to the destruction of the integrity of cell membrane and mitochondrial membrane, thus increasing the permeability of cell membrane and leading to cell edema and necrosis. MPO is a member of the heme peroxidase superfamily (Denning et al., <xref ref-type="bibr" rid="B9">2019</xref>; Liu et al., <xref ref-type="bibr" rid="B25">2020</xref>). Its main function is to kill microorganisms in phagocytes and form oxidizing free radicals to participate in many processes of regulating inflammatory responses. When inflammation occurs in the body, the production of MPO increases, resulting in cell damage (Ward and Fattahi, <xref ref-type="bibr" rid="B52">2019</xref>), while higher levels of MPO, on day 1, were able to predict 90-day mortality (Bonaventura et al., <xref ref-type="bibr" rid="B3">2020</xref>). After 14 days of feeding PCP, the MDA and MPO levels were maintained at low levels, and the expressions of GSH and SOD were higher.</p>
<p>People with asplenia or hyposplenism are at an increased risk of fulminant sepsis which carries a high mortality rate (Kanhutu et al., <xref ref-type="bibr" rid="B16">2017</xref>), and it is proved that splenic function is particularly important for patients with sepsis. Splenic cellular histopathology is one of the direct methods to evaluate the splenic injury, and these outcomes were consistent with the results of improved cytoarchitecture in H&#x00026;E staining (Suttie, <xref ref-type="bibr" rid="B41">2006</xref>; Coccolini et al., <xref ref-type="bibr" rid="B8">2019</xref>). FoxP3<sup>&#x0002B;</sup> regulatory T cells (Treg), a mature T cell subset with regulatory functions, play an important role in immune homeostasis, allergic reaction, tumor immunity, and transplantation tolerance (Kurup et al., <xref ref-type="bibr" rid="B19">2017</xref>). Treg is a good candidate owing to explaining the impairment of the CD4<sup>&#x0002B;</sup> T-cell compartment observed during sepsis due to their highly suppressive function (Qureshi et al., <xref ref-type="bibr" rid="B35">2011</xref>). Moreover, the number of Treg cells has upregulated in early-stage patients with sepsis (Leng et al., <xref ref-type="bibr" rid="B21">2013</xref>). Therefore, Treg cells might be contributed to the higher morbidity and mortality in patients with sepsis (Xu et al., <xref ref-type="bibr" rid="B55">2020</xref>), and the role of Treg cells in the immune response to infection has attracted wide attention (Nascimento et al., <xref ref-type="bibr" rid="B30">2017</xref>). While the first line defenders are combating infection, Treg cells respond to infection by suppressing excessive immune responses elicited by other cells of the adaptive immune system, in turn, further shaped by increased numbers of Treg cells (Huang et al., <xref ref-type="bibr" rid="B14">2010</xref>). In current findings from this study, the expression of Treg cells significantly increased after FP-induced sepsis; nevertheless, decreased FoxP3-labeled cells in FP-induced sepsis and PCP pretreated mice were observed.</p>
<p>Until recently, apoptosis is the best-known form of programmed cell death and resulted in the premature death of cells in living tissue by autolysis (Moreno-Gonzalez et al., <xref ref-type="bibr" rid="B29">2016</xref>); some studies have shown that immune cell apoptosis is directly related to the pathogenesis (Huang et al., <xref ref-type="bibr" rid="B15">2019</xref>; Chen and Wei, <xref ref-type="bibr" rid="B7">2021</xref>) and is the major mechanism of lymphocyte death, which is one of the reasons for the gradual decrease in the number of immune cells in sepsis (Aziz et al., <xref ref-type="bibr" rid="B2">2014</xref>). Thereby, a functionally regulated apoptotic program in thymus and splenic cells may provide a promising strategy for combating FP-induced sepsis. Thereby, we reasoned that the anti-apoptotic biological activity of PCP might be one of the underlying molecular mechanisms of protective effects against FP-induced sepsis.</p>
<p>Taken together, our current findings disclose that PCP exerts a promising immunity protective effect against FP-induced sepsis, suggesting PCP&#x00027;s potential perspective of clinical application. The current findings showed that FP-induced and PCP-pretreated sepsis mice resulted in lower TNF-&#x003B1;, IL-6, and IL-1&#x003B2; contents in plasma, downregulating expression of Treg cells in the spleen. Consequently, we concluded that PCP pretreatment inhibited MPO and MDA release, eventually blocking apoptosis. Furthermore, the underlying molecular mechanisms associated with PCP-mediated cytoprotection warrant should be discussed, respectively.</p>
</sec>
<sec id="s5">
<title>Limitations</title>
<p>This study has several limitations. First, the concentration of PCP is the key factor to determine the pharmacological effect <italic>in vivo</italic>, and we did not determine under the present condition. Second, we only injected with 1 mg/g of feces according to previous reports and did not conduct relevant studies on dose gradient. The number of feces may have imparity pathophysiological. Our results only suggest that PCP 400 mg/kg/day is effective in preventing sepsis caused by 1 mg/g FP-induced sepsis. Finally, although many people in East Asia have been taking PCP orally for a long time, PCP was fed to mice 14 days in advance. Therefore, these results only suggest that PCP has certain anti-inflammatory and protective effects on FIP-induced mice. The relevant studies on the therapeutic effects of PCP on mice with fecal peritonitis-induced sepsis were absent, and we will continue to do relevant studies. Finally, although some evidence has emerged, we have not been able to connect the evidence into a complete pathway to a specific mechanism and block or overexpression of relevant upstream and downstream pathways, and further studies are needed to explore the specific mechanism of these pharmacological effects.</p>
</sec>
<sec sec-type="conclusions" id="s6">
<title>Conclusion</title>
<p>The results in this study suggest that PCPs have pharmacological activity against FP-induced sepsis, by the potential molecular mechanism of inhibiting splenic cell apoptosis, inflammatory stress, and oxidative stress.</p>
</sec>
<sec sec-type="data-availability" id="s7">
<title>Data Availability Statement</title>
<p>The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.</p>
</sec>
<sec id="s8">
<title>Ethics Statement</title>
<p>The animal study was reviewed and approved by the Institutional Animal Care and Use Committee at Naval Medical University.</p>
</sec>
<sec id="s9">
<title>Author Contributions</title>
<p>YW performed mostly experiments, analyzed the data, and drafted the manuscript. DL and HW analyzed the data and critically revised the manuscript. DL contributed to the data analysis and interpretation. XW conceived and designed the study. All authors substantially contributed to editing, revising, and finalizing the manuscript and read and approved the final manuscript.</p>
</sec>
<sec sec-type="funding-information" id="s10">
<title>Funding</title>
<p>This work was supported by the Shanghai Natural Science Foundation (19ZR1456600), the Shanghai Pujiang Program (2020PJD059), the Youth Cultivation Project for Special Basic Medical Research of the First Affiliated Hospital of Naval Medical University (2021JCQN02), and the Incubator Program for Startups of the 980th Hospital of the Joint Logistic Support Force (FYJHMS-04).</p>
</sec>
<sec sec-type="COI-statement" id="conf1">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s11">
<title>Publisher&#x00027;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Athanazio</surname> <given-names>R. A</given-names></name></person-group>. (<year>2003</year>). MB, MJ Freitas Jr, DN Santana, FC Ventin, GC Andrade, JM Teles, SA Souza-Filho, <article-title>OH Messeder Epidemiologic analysis of patients admitted to the intensive care unit in a general hospital</article-title>. <source>Crit. Care</source>. 7, 105. <pub-id pub-id-type="doi">10.1186/cc2301</pub-id></citation>
</ref>
<ref id="B2">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aziz</surname> <given-names>M.</given-names></name> <name><surname>Jacob</surname> <given-names>A.</given-names></name> <name><surname>Wang</surname> <given-names>P.</given-names></name></person-group> (<year>2014</year>). <article-title>Revisiting caspases in sepsis</article-title>. <source>Cell Death Dis</source>. 5, e1526. <pub-id pub-id-type="doi">10.1038/cddis.2014.488</pub-id><pub-id pub-id-type="pmid">25412304</pub-id></citation></ref>
<ref id="B3">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bonaventura</surname> <given-names>A.</given-names></name> <name><surname>Carbone</surname> <given-names>F.</given-names></name> <name><surname>Vecchie</surname> <given-names>A.</given-names></name> <name><surname>Meessen</surname> <given-names>J.</given-names></name> <name><surname>Ferraris</surname> <given-names>S.</given-names></name> <name><surname>Beck</surname> <given-names>E.</given-names></name></person-group> (<year>2020</year>). <article-title>The role of resistin and myeloperoxidase in severe sepsis and septic shock: results from the ALBIOS trial</article-title>. <source>Eur. J. Clin. Invest</source>. 50, e13333. <pub-id pub-id-type="doi">10.1111/eci.13333</pub-id><pub-id pub-id-type="pmid">32585739</pub-id></citation></ref>
<ref id="B4">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bosmann</surname> <given-names>M.</given-names></name> <name><surname>Ward</surname> <given-names>P. A.</given-names></name></person-group> (<year>2013</year>). <article-title>The inflammatory response in sepsis</article-title>. <source>Trends Immunol</source>. <volume>34</volume>, <fpage>129</fpage>&#x02013;<lpage>136</lpage>. <pub-id pub-id-type="doi">10.1016/j.it.2012.09.004</pub-id><pub-id pub-id-type="pmid">23036432</pub-id></citation></ref>
<ref id="B5">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cecconi</surname> <given-names>M.</given-names></name> <name><surname>Evans</surname> <given-names>L.</given-names></name> <name><surname>Levy</surname> <given-names>M.</given-names></name> <name><surname>Rhodes</surname> <given-names>A.</given-names></name></person-group> (<year>2018</year>). <article-title>Sepsis and septic shock</article-title>. <source>Lancet</source>. <volume>392</volume>, <fpage>75</fpage>&#x02013;<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(18)30696-2</pub-id><pub-id pub-id-type="pmid">29937192</pub-id></citation></ref>
<ref id="B6">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chaturvedi</surname> <given-names>V.</given-names></name> <name><surname>Marsh</surname> <given-names>R. A.</given-names></name> <name><surname>Zoref-Lorenz</surname> <given-names>A.</given-names></name> <name><surname>Owsley</surname> <given-names>E.</given-names></name> <name><surname>Nguyen</surname> <given-names>T. C.</given-names></name></person-group> (<year>2021</year>). <article-title>T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis</article-title>. <source>Blood</source>. <volume>137</volume>, <fpage>2337</fpage>&#x02013;<lpage>2346</lpage>. <pub-id pub-id-type="doi">10.1182/blood.2020009499</pub-id><pub-id pub-id-type="pmid">33512385</pub-id></citation></ref>
<ref id="B7">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>J.</given-names></name> <name><surname>Wei</surname> <given-names>H.</given-names></name></person-group> (<year>2021</year>). <article-title>Immune intervention in sepsis</article-title>. <source>Front. Pharmacol</source>. 12, 718089. <pub-id pub-id-type="doi">10.3389/fphar.2021.718089</pub-id><pub-id pub-id-type="pmid">34335278</pub-id></citation></ref>
<ref id="B8">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coccolini</surname> <given-names>F.</given-names></name> <name><surname>Fugazzola</surname> <given-names>P.</given-names></name> <name><surname>Morganti</surname> <given-names>L.</given-names></name> <name><surname>Ceresoli</surname> <given-names>M.</given-names></name> <name><surname>Magnone</surname> <given-names>S.</given-names></name> <name><surname>Montori</surname> <given-names>G.</given-names></name></person-group> (<year>2019</year>). <article-title>The World Society of Emergency Surgery (WSES) spleen trauma classification: a useful tool in the management of splenic trauma</article-title>. <source>World J. Emerg. Surg</source>. 14, 30. <pub-id pub-id-type="doi">10.1186/s13017-019-0246-1</pub-id><pub-id pub-id-type="pmid">31236130</pub-id></citation></ref>
<ref id="B9">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Denning</surname> <given-names>N. L.</given-names></name> <name><surname>Aziz</surname> <given-names>M.</given-names></name> <name><surname>Gurien</surname> <given-names>S. D.</given-names></name> <name><surname>Wang</surname> <given-names>P.</given-names></name></person-group> (<year>2019</year>). <article-title>DAMPs and NETs in sepsis</article-title>. <source>Front. Immunol</source>. 10, 2536. <pub-id pub-id-type="doi">10.3389/fimmu.2019.02536</pub-id><pub-id pub-id-type="pmid">31736963</pub-id></citation></ref>
<ref id="B10">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname> <given-names>L.</given-names></name> <name><surname>Rhodes</surname> <given-names>A.</given-names></name> <name><surname>Alhazzani</surname> <given-names>W.</given-names></name> <name><surname>Antonelli</surname> <given-names>M.</given-names></name> <name><surname>Coopersmith</surname> <given-names>C. M.</given-names></name> <name><surname>French</surname> <given-names>C.</given-names></name></person-group> (<year>2021</year>). <article-title>Surviving sepsis campaign: international guidelines for management of sepsis and septic shock (2021)</article-title>. <source>Intensive Care Med</source>. <volume>47</volume>, <fpage>1181</fpage>&#x02013;<lpage>1247</lpage>. <pub-id pub-id-type="doi">10.1007/s00134-021-06506-y</pub-id><pub-id pub-id-type="pmid">34599691</pub-id></citation></ref>
<ref id="B11">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grondman</surname> <given-names>I.</given-names></name> <name><surname>Pirvu</surname> <given-names>A.</given-names></name> <name><surname>Riza</surname> <given-names>A.</given-names></name> <name><surname>Ioana</surname> <given-names>M.</given-names></name> <name><surname>Netea</surname> <given-names>M. G.</given-names></name></person-group> (<year>2020</year>). <article-title>Biomarkers of inflammation and the etiology of sepsis</article-title>. <source>Biochem. Soc Trans</source>. <volume>48</volume>, <fpage>1</fpage>&#x02013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1042/BST20190029</pub-id><pub-id pub-id-type="pmid">32049312</pub-id></citation></ref>
<ref id="B12">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname> <given-names>L. i. W</given-names></name> <name><surname>Xu</surname> <given-names>S.</given-names></name> <name><surname>Li</surname> <given-names>D.</given-names></name> <name><surname>Cao</surname> <given-names>B.</given-names></name> <name><surname>Tian</surname> <given-names>N.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Polysaccharide of Atractylodes macrocephala Koidz (PAMK) relieves immunosuppression in cyclophosphamide-treated geese by maintaining a humoral and cellular immune balance</article-title>. <source>Molecules</source>. 23. <pub-id pub-id-type="doi">10.3390/molecules23040932</pub-id><pub-id pub-id-type="pmid">29673208</pub-id></citation></ref>
<ref id="B13">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gustine</surname> <given-names>J. N.</given-names></name> <name><surname>Jones</surname> <given-names>D.</given-names></name></person-group> (<year>2021</year>). <article-title>Immunopathology of hyperinflammation in COVID-19</article-title>. <source>Am. J. Pathol</source>. <volume>191</volume>, <fpage>4</fpage>&#x02013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajpath.2020.08.009</pub-id><pub-id pub-id-type="pmid">32919977</pub-id></citation></ref>
<ref id="B14">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>L. F.</given-names></name> <name><surname>Yao</surname> <given-names>Y. M.</given-names></name> <name><surname>Dong</surname> <given-names>N.</given-names></name> <name><surname>He</surname> <given-names>Y. u. Y</given-names></name> <name><surname>Sheng</surname> <given-names>L. X.</given-names></name> <etal/></person-group>. (<year>2010</year>). <article-title>between regulatory T cell activity and sepsis and outcome of severely burned patients: a prospective, observational study</article-title>. <source>Crit. Care</source>. 14, R3. <pub-id pub-id-type="doi">10.1186/cc8232</pub-id><pub-id pub-id-type="pmid">20064232</pub-id></citation></ref>
<ref id="B15">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>M.</given-names></name> <name><surname>Cai</surname> <given-names>S.</given-names></name> <name><surname>Su</surname> <given-names>J.</given-names></name></person-group> (<year>2019</year>). <article-title>The pathogenesis of sepsis and potential therapeutic targets</article-title>. <source>Int. J. Mol. Sci</source>. 20.(21). <pub-id pub-id-type="doi">10.3390/ijms20215376</pub-id><pub-id pub-id-type="pmid">31671729</pub-id></citation></ref>
<ref id="B16">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kanhutu</surname> <given-names>K.</given-names></name> <name><surname>Jones</surname> <given-names>P.</given-names></name> <name><surname>Cheng</surname> <given-names>A. C.</given-names></name> <name><surname>Grannell</surname> <given-names>L.</given-names></name> <name><surname>Best</surname> <given-names>E.</given-names></name> <name><surname>Spelman</surname> <given-names>D.</given-names></name></person-group> (<year>2017</year>). <article-title>Spleen Australia guidelines for the prevention of sepsis in patients with asplenia and hyposplenism in Australia and New Zealand</article-title>. <source>Intern. Med. J</source>. <volume>47</volume>, <fpage>848</fpage>&#x02013;<lpage>855</lpage>. <pub-id pub-id-type="doi">10.1111/imj.13348</pub-id><pub-id pub-id-type="pmid">27925427</pub-id></citation></ref>
<ref id="B17">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>J. H.</given-names></name> <name><surname>Sim</surname> <given-names>H. A.</given-names></name> <name><surname>Jung</surname> <given-names>D. Y.</given-names></name> <name><surname>Lim</surname> <given-names>E. Y.</given-names></name> <name><surname>Kim</surname> <given-names>Y. T.</given-names></name> <name><surname>Kim</surname> <given-names>B. J.</given-names></name></person-group> (<year>2019</year>). <article-title>Poria cocus wolf extract ameliorates hepatic steatosis through regulation of lipid metabolism, inhibition of er stress, and activation of autophagy via AMPK activation</article-title>. <source>Int. J. Mol. Sci</source>. 20.(19). <pub-id pub-id-type="doi">10.3390/ijms20194801</pub-id><pub-id pub-id-type="pmid">31569635</pub-id></citation></ref>
<ref id="B18">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kobira</surname> <given-names>S.</given-names></name> <name><surname>Atsumi</surname> <given-names>T.</given-names></name> <name><surname>Kakiuchi</surname> <given-names>N.</given-names></name> <name><surname>Mikage</surname> <given-names>M.</given-names></name></person-group> (<year>2012</year>). <article-title>Difference in cultivation characteristics and genetic polymorphism between Chinese and Japanese strains of Wolfiporia cocos Ryvarden et Gilbertson (Poria cocos Wolf)</article-title>. <source>J. Nat. Med</source>. <volume>66</volume>, <fpage>493</fpage>&#x02013;<lpage>499</lpage>. <pub-id pub-id-type="doi">10.1007/s11418-011-0612-0</pub-id><pub-id pub-id-type="pmid">22127530</pub-id></citation></ref>
<ref id="B19">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kurup</surname> <given-names>S. P.</given-names></name> <name><surname>Obeng-Adjei</surname> <given-names>N.</given-names></name> <name><surname>Anthony</surname> <given-names>S. M.</given-names></name> <name><surname>Traore</surname> <given-names>B.</given-names></name> <name><surname>Doumbo</surname> <given-names>O. K.</given-names></name> <name><surname>Butler</surname> <given-names>N. S.</given-names></name></person-group> (<year>2017</year>). <article-title>Regulatory T cells impede acute and long-term immunity to blood-stage malaria through CTLA-4</article-title>. <source>Nat. Med</source>. <volume>23</volume>, <fpage>1220</fpage>&#x02013;<lpage>1225</lpage>. <pub-id pub-id-type="doi">10.1038/nm.4395</pub-id><pub-id pub-id-type="pmid">28892065</pub-id></citation></ref>
<ref id="B20">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>S. R.</given-names></name> <name><surname>Lee</surname> <given-names>S.</given-names></name> <name><surname>Moon</surname> <given-names>E.</given-names></name> <name><surname>Park</surname> <given-names>H. J.</given-names></name> <name><surname>Park</surname> <given-names>H. B.</given-names></name> <name><surname>Kim</surname> <given-names>K. H.</given-names></name></person-group> (<year>2017</year>). <article-title>Bioactivity-guided isolation of anti-inflammatory triterpenoids from the sclerotia of Poria cocos using LPS-stimulated Raw264.7 cells</article-title>. <source>Bioorg. Chem</source>. <volume>70</volume>, <fpage>94</fpage>&#x02013;<lpage>99</lpage>. <pub-id pub-id-type="doi">10.1016/j.bioorg.2016.11.012</pub-id><pub-id pub-id-type="pmid">27912907</pub-id></citation></ref>
<ref id="B21">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leng</surname> <given-names>F. Y.</given-names></name> <name><surname>Liu</surname> <given-names>J. L.</given-names></name> <name><surname>Liu</surname> <given-names>Z. J.</given-names></name> <name><surname>Yin</surname> <given-names>J. Y.</given-names></name> <name><surname>Qu</surname> <given-names>H. P.</given-names></name></person-group> (<year>2013</year>). <article-title>Increased proportion of CD4(&#x0002B;)CD25(&#x0002B;)Foxp3(&#x0002B;) regulatory T cells during early-stage sepsis in ICU patients</article-title>. <source>J. Microbiol. Immunol. Infect</source>. <volume>46</volume>, <fpage>338</fpage>&#x02013;<lpage>344</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmii.2012.06.012</pub-id><pub-id pub-id-type="pmid">22921804</pub-id></citation></ref>
<ref id="B22">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>L.</given-names></name> <name><surname>Li.</surname> <given-names>Y</given-names></name> <name><surname>Lu</surname> <given-names>X.</given-names></name> <name><surname>Chaurasiya</surname> <given-names>Y.</given-names></name> <name><surname>Mi</surname> <given-names>B.</given-names></name> <name><surname>Shi</surname> <given-names>G.</given-names></name></person-group> (<year>2020</year>). <article-title>D, et al. Co-delivery of Poria cocos extract and doxorubicin as an &#x00027;all-in-one&#x00027; nanocarrier to combat breast cancer multidrug resistance during chemotherapy</article-title>. <source>Nanomedicine</source>. 23, 102095. <pub-id pub-id-type="doi">10.1016/j.nano.2019.102095</pub-id><pub-id pub-id-type="pmid">31669856</pub-id></citation></ref>
<ref id="B23">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>L.</given-names></name> <name><surname>Zuo</surname> <given-names>Z. T.</given-names></name> <name><surname>Wang</surname> <given-names>Y. Z.</given-names></name></person-group> (<year>2022</year>). <article-title>the traditional usages, chemical components and pharmacological activities of Wolfiporia cocos: a review</article-title>. <source>Am. J. Chin. Med</source>. <volume>50</volume>, <fpage>389</fpage>&#x02013;<lpage>440</lpage>. <pub-id pub-id-type="doi">10.1142/S0192415X22500161</pub-id><pub-id pub-id-type="pmid">35300566</pub-id></citation></ref>
<ref id="B24">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>X.</given-names></name> <name><surname>He</surname> <given-names>Y.</given-names></name> <name><surname>Zeng</surname> <given-names>P.</given-names></name> <name><surname>Liu</surname> <given-names>Y.</given-names></name> <name><surname>Zhang</surname> <given-names>M.</given-names></name> <name><surname>Hao</surname> <given-names>C.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Molecular basis for Poria cocos mushroom polysaccharide used as an antitumour drug in China</article-title>. <source>J. Cell Mol. Med</source>. <volume>23</volume>, <fpage>4</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1111/jcmm.13564</pub-id><pub-id pub-id-type="pmid">30444050</pub-id></citation></ref>
<ref id="B25">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>Y.</given-names></name> <name><surname>Liu.</surname> <given-names>H</given-names></name> <name><surname>Wang</surname> <given-names>Y.</given-names></name> <name><surname>Restrepo</surname> <given-names>M.</given-names></name> <name><surname>Wang</surname> <given-names>R. J.</given-names></name> <name><surname>Kalogeris</surname> <given-names>D.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Myeloperoxidase instigates proinflammatory responses in a cecal ligation and puncture rat model of sepsis</article-title>. <source>Am. J. Physiol. Heart. Circ. Physiol</source>. <volume>319</volume>, <fpage>H705</fpage>&#x02013;<lpage>H21</lpage>. <pub-id pub-id-type="doi">10.1152/ajpheart.00440.2020</pub-id><pub-id pub-id-type="pmid">32762560</pub-id></citation></ref>
<ref id="B26">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>London</surname> <given-names>N. R.</given-names></name> <name><surname>Zhu</surname> <given-names>W.</given-names></name> <name><surname>Bozza</surname> <given-names>F. A.</given-names></name> <name><surname>Smith</surname> <given-names>M. C.</given-names></name> <name><surname>Greif</surname> <given-names>D. M.</given-names></name> <name><surname>Sorensen</surname> <given-names>L. K.</given-names></name></person-group> (<year>2010</year>). <article-title>Targeting Robo4-dependent Slit signaling to survive the cytokine storm in sepsis and influenza</article-title>. <source>Sci. Transl. Med</source>. 2, 23. <pub-id pub-id-type="doi">10.1126/scitranslmed.3000678</pub-id><pub-id pub-id-type="pmid">20375003</pub-id></citation></ref>
<ref id="B27">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lonsdale</surname> <given-names>D. O.</given-names></name> <name><surname>Shah</surname> <given-names>R. V.</given-names></name> <name><surname>Lipman</surname> <given-names>J.</given-names></name></person-group> (<year>2020</year>). <article-title>Infection, sepsis and the inflammatory response: mechanisms and therapy</article-title>. <source>Front. Med. (Lausanne)</source>. 7, 588863. <pub-id pub-id-type="doi">10.3389/fmed.2020.588863</pub-id><pub-id pub-id-type="pmid">33344475</pub-id></citation></ref>
<ref id="B28">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mahla</surname> <given-names>R. S.</given-names></name> <name><surname>Reddy</surname> <given-names>M. C.</given-names></name> <name><surname>Prasad</surname> <given-names>D. V.</given-names></name> <name><surname>Kumar</surname> <given-names>H.</given-names></name></person-group> (<year>2013</year>). <article-title>Sweeten PAMPs: role of sugar complexed PAMPs in innate immunity and vaccine biology</article-title>. <source>Front. Immunol</source>. 4, 248. <pub-id pub-id-type="doi">10.3389/fimmu.2013.00248</pub-id><pub-id pub-id-type="pmid">24032031</pub-id></citation></ref>
<ref id="B29">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moreno-Gonzalez</surname> <given-names>G.</given-names></name> <name><surname>Vandenabeele</surname> <given-names>P.</given-names></name> <name><surname>Krysko</surname> <given-names>D. V.</given-names></name></person-group> (<year>2016</year>). <article-title>Necroptosis: a novel cell death modality and its potential relevance for critical care medicine</article-title>. <source>Am J Respir Crit Care Med</source>. <volume>194</volume>, <fpage>415</fpage>&#x02013;<lpage>428</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201510-2106CI</pub-id><pub-id pub-id-type="pmid">27285640</pub-id></citation></ref>
<ref id="B30">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nascimento</surname> <given-names>D. C.</given-names></name> <name><surname>Melo</surname> <given-names>P. H.</given-names></name> <name><surname>Pineros</surname> <given-names>A. R.</given-names></name> <name><surname>Ferreira</surname> <given-names>R. G.</given-names></name> <name><surname>Colon</surname> <given-names>D. F.</given-names></name> <name><surname>Donate</surname> <given-names>P. B.</given-names></name></person-group> (<year>2017</year>). <article-title>IL-33 contributes to sepsis-induced long-term immunosuppression by expanding the regulatory T cell population</article-title>. <source>Nat. Commun</source>. 8, 14919. <pub-id pub-id-type="doi">10.1038/ncomms14919</pub-id><pub-id pub-id-type="pmid">28374774</pub-id></citation></ref>
<ref id="B31">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ngamsri</surname> <given-names>K. C.</given-names></name> <name><surname>Fabian</surname> <given-names>F.</given-names></name> <name><surname>Fuhr</surname> <given-names>A.</given-names></name> <name><surname>Gamper-Tsigaras</surname> <given-names>J.</given-names></name> <name><surname>Straub</surname> <given-names>A.</given-names></name> <name><surname>Fecher</surname> <given-names>D.</given-names></name></person-group> (<year>2021</year>). <article-title>Sevoflurane exerts protective effects in murine peritonitis-induced sepsis via hypoxia-inducible factor 1alpha/adenosine A2B receptor signaling</article-title>. <source>Anesthesiology</source>. <volume>135</volume>, <fpage>136</fpage>&#x02013;<lpage>150</lpage>. <pub-id pub-id-type="doi">10.1097/ALN.0000000000003788</pub-id><pub-id pub-id-type="pmid">33914856</pub-id></citation></ref>
<ref id="B32">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nie</surname> <given-names>A.</given-names></name> <name><surname>Chao</surname> <given-names>Y.</given-names></name> <name><surname>Zhang</surname> <given-names>X.</given-names></name> <name><surname>Jia</surname> <given-names>W.</given-names></name> <name><surname>Zhou</surname> <given-names>Z.</given-names></name> <name><surname>Zhu</surname> <given-names>C.</given-names></name></person-group> (<year>2020</year>). <article-title>Phytochemistry and Pharmacological Activities of Wolfiporia cocos (F.A. Wolf) Ryvarden and Gilb</article-title>. <source>Front Pharmacol</source>. 11, 505249. <pub-id pub-id-type="doi">10.3389/fphar.2020.505249</pub-id><pub-id pub-id-type="pmid">33071776</pub-id></citation></ref>
<ref id="B33">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pizzino</surname> <given-names>G.</given-names></name> <name><surname>Irrera</surname> <given-names>N.</given-names></name> <name><surname>Cucinotta</surname> <given-names>M.</given-names></name> <name><surname>Pallio</surname> <given-names>G.</given-names></name> <name><surname>Mannino</surname> <given-names>F.</given-names></name> <name><surname>Arcoraci</surname> <given-names>V.</given-names></name></person-group> (<year>2017</year>). <article-title>Oxidative stress: harms and benefits for human health</article-title>. <source>Oxid. Med. Cell Longev</source>. 2017, 8416763. <pub-id pub-id-type="doi">10.1155/2017/8416763</pub-id><pub-id pub-id-type="pmid">28819546</pub-id></citation></ref>
<ref id="B34">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pu</surname> <given-names>Y.</given-names></name> <name><surname>Liu</surname> <given-names>Z.</given-names></name> <name><surname>Tian</surname> <given-names>H.</given-names></name> <name><surname>Bao</surname> <given-names>Y.</given-names></name></person-group> (<year>2019</year>). <article-title>The immunomodulatory effect of Poria cocos polysaccharides is mediated by the Ca(2&#x0002B;)/PKC/p38/NF-kappaB signaling pathway in macrophages</article-title>. <source>Int. Immunopharmacol</source>. <volume>72</volume>, <fpage>252</fpage>&#x02013;<lpage>257</lpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2019.04.017</pub-id><pub-id pub-id-type="pmid">31003002</pub-id></citation></ref>
<ref id="B35">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Qureshi</surname> <given-names>O. S.</given-names></name> <name><surname>Zheng</surname> <given-names>Y.</given-names></name> <name><surname>Nakamura</surname> <given-names>K.</given-names></name> <name><surname>Attridge</surname> <given-names>K.</given-names></name> <name><surname>Manzotti</surname> <given-names>C.</given-names></name> <name><surname>Schmidt</surname> <given-names>E. M.</given-names></name></person-group> (<year>2011</year>). <article-title>Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4</article-title>. <source>Science</source>. <volume>332</volume>, <fpage>600</fpage>&#x02013;<lpage>603</lpage>. <pub-id pub-id-type="doi">10.1126/science.1202947</pub-id><pub-id pub-id-type="pmid">21474713</pub-id></citation></ref>
<ref id="B36">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ramirez-Zuniga</surname> <given-names>I.</given-names></name> <name><surname>Rubin</surname> <given-names>J. E.</given-names></name> <name><surname>Swigon</surname> <given-names>D.</given-names></name> <name><surname>Redl</surname> <given-names>H.</given-names></name> <name><surname>Clermont</surname> <given-names>G.</given-names></name></person-group> (<year>2021</year>). <article-title>A data-driven model of the role of energy in sepsis</article-title>. <source>J Theor Biol</source>. 2021, 110948. <pub-id pub-id-type="doi">10.1016/j.jtbi.2021.110948</pub-id><pub-id pub-id-type="pmid">34757193</pub-id></citation></ref>
<ref id="B37">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosen</surname> <given-names>D. A.</given-names></name> <name><surname>Seki</surname> <given-names>S. M.</given-names></name> <name><surname>Fernandez-Castaneda</surname> <given-names>A.</given-names></name> <name><surname>Beiter</surname> <given-names>R. M.</given-names></name> <name><surname>Eccles</surname> <given-names>J. D.</given-names></name> <name><surname>Woodfolk</surname> <given-names>J. A.</given-names></name></person-group> (<year>2019</year>). <article-title>Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis</article-title>. <source>Sci. Transl. Med</source>. 11. <pub-id pub-id-type="doi">10.1126/scitranslmed.aau5266</pub-id><pub-id pub-id-type="pmid">30918112</pub-id></citation></ref>
<ref id="B38">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rudd</surname> <given-names>K. E.</given-names></name> <name><surname>Johnson</surname> <given-names>S. C.</given-names></name> <name><surname>Agesa</surname> <given-names>K. M.</given-names></name> <name><surname>Shackelford</surname> <given-names>K. A.</given-names></name> <name><surname>Tsoi</surname> <given-names>D.</given-names></name> <name><surname>Kievlan</surname> <given-names>D. R.</given-names></name></person-group> (<year>2020</year>). <article-title>Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study</article-title>. <source>Lancet</source>. <volume>395</volume>, <fpage>200</fpage>&#x02013;<lpage>211</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(19)32989-7</pub-id><pub-id pub-id-type="pmid">31954465</pub-id></citation></ref>
<ref id="B39">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname> <given-names>A. Y.</given-names></name> <name><surname>Wang</surname> <given-names>T. S.</given-names></name> <name><surname>Huang</surname> <given-names>M. H.</given-names></name> <name><surname>Liao</surname> <given-names>C. H.</given-names></name> <name><surname>Chen</surname> <given-names>S. J.</given-names></name> <name><surname>Lin</surname> <given-names>C. C.</given-names></name></person-group> (<year>2005</year>). <article-title>Antioxidant and antiplatelet effects of dang-gui-shao-yao-san on human blood cells</article-title>. <source>Am. J. Chin. Med</source>. <volume>33</volume>, <fpage>747</fpage>&#x02013;<lpage>758</lpage>. <pub-id pub-id-type="doi">10.1142/S0192415X05003351</pub-id><pub-id pub-id-type="pmid">16265987</pub-id></citation></ref>
<ref id="B40">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shrum</surname> <given-names>B.</given-names></name> <name><surname>Anantha</surname> <given-names>R. V.</given-names></name> <name><surname>Xu</surname> <given-names>S. X.</given-names></name> <name><surname>Donnelly</surname> <given-names>M.</given-names></name> <name><surname>Haeryfar</surname> <given-names>S. M.</given-names></name> <name><surname>McCormick</surname> <given-names>J. K.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>A robust scoring system to evaluate sepsis severity in an animal model</article-title>. <source>BMC Res. Notes</source>. 7, 233. <pub-id pub-id-type="doi">10.1186/1756-0500-7-233</pub-id><pub-id pub-id-type="pmid">24725742</pub-id></citation></ref>
<ref id="B41">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suttie</surname> <given-names>A. W</given-names></name></person-group>. (<year>2006</year>). <article-title>Histopathology of the spleen</article-title>. <source>Toxicol. Pathol</source>. <volume>34</volume>, <fpage>466</fpage>&#x02013;<lpage>503</lpage>. <pub-id pub-id-type="doi">10.1080/01926230600867750</pub-id><pub-id pub-id-type="pmid">17067940</pub-id></citation></ref>
<ref id="B42">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tridente</surname> <given-names>A.</given-names></name> <name><surname>Clarke</surname> <given-names>G. M.</given-names></name> <name><surname>Walden</surname> <given-names>A.</given-names></name></person-group> (<year>2014</year>). <person-group person-group-type="editor"><name><surname>McKechnie</surname> <given-names>S</given-names></name> <name><surname>Hutton</surname> <given-names>P</given-names></name> <name><surname>Mills</surname> <given-names>GH</given-names></name> <etal/></person-group>. <article-title>Patients with faecal peritonitis admitted to European intensive care units: an epidemiological survey of the GenOSept cohort</article-title>. <source>Intensive Care Med</source>. <volume>40</volume>, <fpage>202</fpage>&#x02013;<lpage>210</lpage>. <pub-id pub-id-type="doi">10.1007/s00134-013-3158-7</pub-id><pub-id pub-id-type="pmid">24306080</pub-id></citation></ref>
<ref id="B43">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Usmani</surname> <given-names>J.</given-names></name> <name><surname>Khan</surname> <given-names>T.</given-names></name> <name><surname>Ahmad</surname> <given-names>R.</given-names></name> <name><surname>Sharma</surname> <given-names>M.</given-names></name></person-group> (<year>2021</year>). <article-title>Potential role of herbal medicines as a novel approach in sepsis treatment</article-title>. <source>Biomed. Pharmacother</source>. 144, 112337. <pub-id pub-id-type="doi">10.1016/j.biopha.2021.112337</pub-id><pub-id pub-id-type="pmid">34688080</pub-id></citation></ref>
<ref id="B44">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>van der Poll</surname> <given-names>T.</given-names></name> <name><surname>Shankar-Hari</surname> <given-names>M.</given-names></name> <name><surname>Wiersinga</surname> <given-names>W. J.</given-names></name></person-group> (<year>2021</year>). <article-title>The immunology of sepsis</article-title>. <source>Immunity</source>. <volume>54</volume>, <fpage>2450</fpage>&#x02013;<lpage>2464</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2021.10.012</pub-id><pub-id pub-id-type="pmid">34758337</pub-id></citation></ref>
<ref id="B45">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vincent</surname> <given-names>J. L.</given-names></name> <name><surname>Sakr</surname> <given-names>Y.</given-names></name> <name><surname>Singer</surname> <given-names>M.</given-names></name> <name><surname>Martin-Loeches</surname> <given-names>I.</given-names></name> <name><surname>Machado</surname> <given-names>F. R.</given-names></name> <name><surname>Marshall</surname> <given-names>J. C.</given-names></name></person-group> (<year>2020</year>). <article-title>Prevalence and outcomes of infection among patients in intensive care units in 2017</article-title>. <source>JAMA</source>. <volume>323</volume>, <fpage>1478</fpage>&#x02013;<lpage>1487</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2020.2717</pub-id><pub-id pub-id-type="pmid">32207816</pub-id></citation></ref>
<ref id="B46">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>H.</given-names></name> <name><surname>Mukerabigwi</surname> <given-names>J. F.</given-names></name> <name><surname>Zhang</surname> <given-names>Y.</given-names></name> <name><surname>Han</surname> <given-names>L.</given-names></name> <name><surname>Jiayinaguli</surname> <given-names>T.</given-names></name> <name><surname>Wang</surname> <given-names>Q.</given-names></name></person-group> (<year>2015</year>). <article-title>In vivo immunological activity of carboxymethylated-sulfated (1&#x02013;&#x0003E;3)-beta-D-glucan from sclerotium of Poria cocos</article-title>. <source>Int. J. Biol. Macromol</source>. <volume>79</volume>, <fpage>511</fpage>&#x02013;<lpage>517</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijbiomac.2015.05.020</pub-id><pub-id pub-id-type="pmid">26014139</pub-id></citation></ref>
<ref id="B47">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>J.</given-names></name> <name><surname>Wang</surname> <given-names>A.</given-names></name> <name><surname>He</surname> <given-names>H.</given-names></name> <name><surname>She</surname> <given-names>X.</given-names></name> <name><surname>He</surname> <given-names>Y.</given-names></name> <name><surname>Li</surname> <given-names>S.</given-names></name></person-group> (<year>2019</year>). <article-title>Trametenolic acid B protects against cerebral ischemia and reperfusion injury through modulation of microRNA-10a and PI3K/Akt/mTOR signaling pathways</article-title>. <source>Biomed. Pharmacother</source>. 112, 108692. <pub-id pub-id-type="doi">10.1016/j.biopha.2019.108692</pub-id><pub-id pub-id-type="pmid">30798122</pub-id></citation></ref>
<ref id="B48">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>N.</given-names></name> <name><surname>Zhang</surname> <given-names>Y.</given-names></name> <name><surname>Wang</surname> <given-names>X.</given-names></name> <name><surname>Huang</surname> <given-names>X.</given-names></name> <name><surname>Fei</surname> <given-names>Y.</given-names></name> <name><surname>Yu</surname> <given-names>Y.</given-names></name></person-group> (<year>2016</year>). <article-title>Antioxidant property of water-soluble polysaccharides from Poria cocos Wolf using different extraction methods</article-title>. <source>Int. J. Biol. Macromol</source>. <volume>83</volume>, <fpage>103</fpage>&#x02013;<lpage>110</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijbiomac.2015.11.032</pub-id><pub-id pub-id-type="pmid">26601761</pub-id></citation></ref>
<ref id="B49">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>X. W.</given-names></name> <name><surname>Wang</surname> <given-names>J. X.</given-names></name></person-group> (<year>2013</year>). <article-title>Pattern recognition receptors acting in innate immune system of shrimp against pathogen infections</article-title>. <source>Fish Shellfish Immunol</source>. <volume>34</volume>, <fpage>981</fpage>&#x02013;<lpage>989</lpage>. <pub-id pub-id-type="doi">10.1016/j.fsi.2012.08.008</pub-id><pub-id pub-id-type="pmid">22960101</pub-id></citation></ref>
<ref id="B50">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>Y.</given-names></name> <name><surname>Zhao</surname> <given-names>L. i. T</given-names></name> <name><surname>Zhang</surname> <given-names>Y.</given-names></name> <name><surname>Liu</surname> <given-names>J.</given-names></name> <name><surname>Contents</surname> <given-names>H.</given-names></name></person-group> (<year>2012</year>). <article-title>of some metabolites in the peel and flesh of the medicinal mushroom Wolfiporia cocos (F.A. Wolf) Ryvarden et Gilb. (higher Basidiomycetes)</article-title>. <source>Int. J. Med. Mushrooms</source>. <volume>14</volume>, <fpage>79</fpage>&#x02013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1615/IntJMedMushr.v14.i1.80</pub-id><pub-id pub-id-type="pmid">22339710</pub-id></citation></ref>
<ref id="B51">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>Y. Z.</given-names></name> <name><surname>Zhang</surname> <given-names>J.</given-names></name> <name><surname>Zhao</surname> <given-names>Y. L.</given-names></name> <name><surname>Shen</surname> <given-names>L.</given-names></name> <name><surname>Li</surname> <given-names>T.</given-names></name> <etal/></person-group>. (<year>2013</year>). <article-title>Mycology, cultivation, traditional uses, phytochemistry and pharmacology of Wolfiporia cocos (Schwein.) Ryvarden et Gilb.: a review</article-title>. <source>J. Ethnopharmacol</source>. <volume>147</volume>, <fpage>265</fpage>&#x02013;<lpage>276</lpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2013.03.027</pub-id><pub-id pub-id-type="pmid">23528366</pub-id></citation></ref>
<ref id="B52">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname> <given-names>P. A.</given-names></name> <name><surname>Fattahi</surname> <given-names>F.</given-names></name></person-group> (<year>2019</year>). <article-title>New strategies for treatment of infectious sepsis</article-title>. <source>J. Leukoc Biol</source>. <volume>106</volume>, <fpage>187</fpage>&#x02013;<lpage>192</lpage>. <pub-id pub-id-type="doi">10.1002/JLB.4MIR1118-425R</pub-id><pub-id pub-id-type="pmid">30821872</pub-id></citation></ref>
<ref id="B53">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>K.</given-names></name> <name><surname>Fan</surname> <given-names>J.</given-names></name> <name><surname>Huang</surname> <given-names>X.</given-names></name> <name><surname>Wu</surname> <given-names>X.</given-names></name> <name><surname>Guo</surname> <given-names>C.</given-names></name></person-group> (<year>2018</year>). <article-title>Hepatoprotective effects exerted by Poria Cocos polysaccharides against acetaminophen-induced liver injury in mice</article-title>. <source>Int. J. Biol. Macromol</source>. <volume>114</volume>, <fpage>137</fpage>&#x02013;<lpage>142</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijbiomac.2018.03.107</pub-id><pub-id pub-id-type="pmid">29572139</pub-id></citation></ref>
<ref id="B54">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>K.</given-names></name> <name><surname>Guo</surname> <given-names>C.</given-names></name> <name><surname>Yang</surname> <given-names>B.</given-names></name> <name><surname>Wu</surname> <given-names>X.</given-names></name> <name><surname>Wang</surname> <given-names>W.</given-names></name></person-group> (<year>2019</year>). <article-title>Antihepatotoxic benefits of Poria cocos polysaccharides on acetaminophen-lesioned livers in vivo and in vitro</article-title>. <source>J. Cell Biochem</source>. <volume>120</volume>, <fpage>7482</fpage>&#x02013;<lpage>7488</lpage>. <pub-id pub-id-type="doi">10.1002/jcb.28022</pub-id><pub-id pub-id-type="pmid">30378160</pub-id></citation></ref>
<ref id="B55">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>T.</given-names></name> <name><surname>Zhao</surname> <given-names>J.</given-names></name> <name><surname>Wang</surname> <given-names>X.</given-names></name> <name><surname>Meng</surname> <given-names>Y.</given-names></name> <name><surname>Zhao</surname> <given-names>Z.</given-names></name> <name><surname>Bao</surname> <given-names>R.</given-names></name></person-group> (<year>2020</year>). <article-title>CXCL4 promoted the production of CD4(&#x0002B;)CD25(&#x0002B;)FOXP3(&#x0002B;)treg cells in mouse sepsis model through regulating STAT5/FOXP3 pathway</article-title>. <source>Autoimmunity</source>. <volume>53</volume>, <fpage>289</fpage>&#x02013;<lpage>296</lpage>. <pub-id pub-id-type="doi">10.1080/08916934.2020.1777283</pub-id><pub-id pub-id-type="pmid">32538218</pub-id></citation></ref>
<ref id="B56">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>Q.</given-names></name> <name><surname>Cong</surname> <given-names>R.</given-names></name> <name><surname>Hu</surname> <given-names>M.</given-names></name> <name><surname>Zhu</surname> <given-names>Y.</given-names></name> <name><surname>Yang</surname> <given-names>X.</given-names></name></person-group> (<year>2017</year>). <article-title>Immunoenhancement of edible fungal polysaccharides (Lentinan, Tremellan, and Pachymaran) on cyclophosphamide-induced immunosuppression in mouse model</article-title>. <source>Evid. Based Complement. Alternat. Med</source>. 2017, 9459156. <pub-id pub-id-type="doi">10.1155/2017/9459156</pub-id><pub-id pub-id-type="pmid">29358974</pub-id></citation></ref>
<ref id="B57">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname> <given-names>L. X.</given-names></name> <name><surname>Xu</surname> <given-names>J.</given-names></name> <name><surname>Wang</surname> <given-names>R. J.</given-names></name> <name><surname>Li</surname> <given-names>H. X.</given-names></name> <name><surname>Tan</surname> <given-names>L.</given-names></name> <name><surname>Chen</surname> <given-names>Y. Z.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Correlation between Quality and geographical origins of poria cocos revealed by qualitative fingerprint profiling and quantitative determination of triterpenoid acids</article-title>. <source>Molecules</source>. 23. <pub-id pub-id-type="doi">10.3390/molecules23092200</pub-id><pub-id pub-id-type="pmid">30200284</pub-id></citation></ref>
</ref-list>
<glossary>
<def-list>
<title>Abbreviations</title>
<def-item><term>PCP</term>
<def><p>Poria Cocos polysaccharide</p></def></def-item>
<def-item><term>FIP</term>
<def><p>fecal-induced peritonitis</p></def></def-item>
<def-item><term>GPx</term>
<def><p>glutathione peroxidase</p></def></def-item>
<def-item><term>SOD</term>
<def><p>superoxide dismutase</p></def></def-item>
<def-item><term>MDA</term>
<def><p>malondialdehyde</p></def></def-item>
<def-item><term>MPO</term>
<def><p>myeloperoxidase</p></def></def-item>
<def-item><term>ICU</term>
<def><p>intensive care unit</p></def></def-item>
<def-item><term>TUNEL</term>
<def><p>dUTP-biotin nick end labeling</p></def></def-item>
<def-item><term>ANOVA</term>
<def><p>analysis of variance</p></def></def-item>
<def-item><term>MSS</term>
<def><p>Murine Sepsis Score</p></def></def-item>
<def-item><term>H&#x00026;E</term>
<def><p>hematoxylin-eosin staining</p></def></def-item>
<def-item><term>DAMPs</term>
<def><p>damage-associated molecular patterns</p></def></def-item>
<def-item><term>ROS</term>
<def><p>reactive oxygen species</p></def></def-item>
<def-item><term>PAMPs</term>
<def><p>pathogen-associated molecular patterns</p></def></def-item>
<def-item><term>PRRs</term>
<def><p>pattern recognition receptors</p></def></def-item>
<def-item><term>SABC</term>
<def><p>strept avidin biotin complex.</p></def></def-item>
</def-list>
</glossary> 
</back>
</article>